Related Experiment Video
Updated: Aug 2, 2026

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals
Published on: May 30, 2013
Is vitamin E supplementation a useful agent in AIDS therapy?
1Nutritional Sciences Program, University of Arizona, Tucson 85724.
Acquired immune deficiency syndrome (AIDS) is a clinical disorder caused by a retrovirus infection, representing the end point in a progressive sequence of immunosuppressive changes. The literature is briefly summarized as to immunological, nutritional and other pathological modifications caused by AIDS, and properties of immunoenhancing, anti-oxidant and undernutrition-restoration of vitamin E supplementation. All these abnormalities in AIDS are similar to those that are stimulated or restored by intake of high doses of vitamin E. The drawbacks of pharmacological therapy like zidovudine (AZT), e.g. deleterious toxic side effects, inability to improve the immune dysfunctions and undernutrition initiated by the retrovirus infection, and finding of AZT-resistant HIV strains, necessitate new strategies for the clinical trials of novel therapies to treat AIDS with the existing medical therapies. Low toxicity nutritional agents with immunoenhancing and antioxidant activities like vitamin E may help to normalize retrovirus-induced immune dysfunctions, undernutrition and other pathological symptoms, thereby retarding the progression of the disease to AIDS. To address this vitamin E therapeutic role in HIV-positive individuals, This paper presents a review of vitamin E-related therapeutic roles in animals and humans, thereby showing why vitamin E supplementation could be used as a useful therapeutic agent in human AIDS therapy. Since there is a paucity of information available regarding the nutritional therapy in AIDS individuals, our purpose is to provide evidence from animal models or humans of the potential therapeutic role of vitamin E supplementation in the treatment of AIDS individuals.
Acquired immune deficiency syndrome (AIDS) is a clinical disorder caused by a retrovirus infection, representing the end point in a progressive sequence of immunosuppressive changes. The literature is briefly summarized as to immunological, nutritional and other pathological modifications caused by AIDS, and properties of immunoenhancing, anti-oxidant and undernutrition-restoration of vitamin E supplementation. All these abnormalities in AIDS are similar to those that are stimulated or restored by intake of high doses of vitamin E. The drawbacks of pharmacological therapy like zidovudine (AZT), e.g. deleterious toxic side effects, inability to improve the immune dysfunctions and undernutrition initiated by the retrovirus infection, and finding of AZT-resistant HIV strains, necessitate new strategies for the clinical trials of novel therapies to treat AIDS with the existing medical therapies. Low toxicity nutritional agents with immunoenhancing and antioxidant activities like vitamin E may help to normalize retrovirus-induced immune dysfunctions, undernutrition and other pathological symptoms, thereby retarding the progression of the disease to AIDS. To address this vitamin E therapeutic role in HIV-positive individuals, This paper presents a review of vitamin E-related therapeutic roles in animals and humans, thereby showing why vitamin E supplementation could be used as a useful therapeutic agent in human AIDS therapy. Since there is a paucity of information available regarding the nutritional therapy in AIDS individuals, our purpose is to provide evidence from animal models or humans of the potential therapeutic role of vitamin E supplementation in the treatment of AIDS individuals.
Related Concept Videos
Retrovirus Life Cycles
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Atherosclerosis III: Management
Inhibitors of Viral Protein Synthesis
Antiprotozoal Agents

